Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

COVID-19

Business & Regulation Business Practice

Crisis Point

| Maryam Mahdi

How is African pharma coping with the COVID-19 pandemic?

Manufacture Vaccines

Success at Speed Part 6: Logistics and Global Availability

| Piergiuseppe Nestola, Amélie Boulais

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Manufacture Vaccines

Success at Speed Part 5: Reducing Costs

| Amélie Boulais, Piergiuseppe Nestola

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

Manufacture Vaccines

Don’t Exclude the Aged

| Stephanie Sutton

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.

Manufacture Vaccines

Success at Speed Part 4: Commercial Manufacturing

| Amélie Boulais, Piergiuseppe Nestola

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Business & Regulation Business Practice

The Pandemic Diaries

| Zahid Tharia, David Underwood, Kenneth Lee, Mike Jagielski, Ger Brophy

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

Manufacture Advanced Medicine

The Cell Therapy Guardians

| James Strachan

We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.

Manufacture Advanced Medicine

How to Deliver a Virtual Conference in Under Two Months

| Queenie Jang

Queenie Jang reveals how the ISCT created an interactive virtual conference in under two months.

Manufacture Vaccines

Success at Speed Part 3: Vaccine Modalities

| Amélie Boulais, Piergiuseppe Nestola

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.

Manufacture Small Molecules

A Year of Challenge and Opportunity

| Maryam Mahdi

How do we manage the fallout caused by the COVID-19 pandemic?


Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register